Home › Compound Library › Insulin Lispro (Humalog)

Insulin Lispro (Humalog)

Hormoneprescriptionsubcutaneous · inferred

Rapid-acting insulin analog with B28/B29 proline-lysine swap that reduces self-association, enabling faster hexamer dissociation and absorption. Onset ~15 min, peak 0.5-1.5h, duration 3-5h. Taken immediately before meals to control postprandial glucose excursions.

Projected serum levels — 10 units (≈ 0.35 mg), once daily

Insulin Lispro (Humalog)
Insulin Lispro (Humalog) modeled serum levels, 10 units (≈ 0.35 mg) once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 10 units (≈ 0.35 mg) once daily (subcutaneous).

Modeled steady state after ~1 days: peak ≈ 0.16 mg, trough ≈ 0.000 mg body load. Population-based estimate over 15 days for a reference dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Hormone
Route modeled
Subcutaneous
Model confidence
inferred
Half-life
1 h
Common dose
10 units (≈ 0.35 mg)
Suggested maximum
60 units/day
Reference dose range
5–60 units (single dose)
Suggested cadence
once daily

Documented interactions

  • moderate
    Insulin Aspart (NovoLog) + Insulin Lispro (Humalog) Stacked effects

    Insulin Aspart (NovoLog) and Insulin Lispro (Humalog) both push the igf1 receptor and insulin receptor in the same direction.

  • moderate
    Insulin Glargine (Lantus) + Insulin Lispro (Humalog) Stacked effects

    Insulin Glargine (Lantus) and Insulin Lispro (Humalog) both push the igf1 receptor and insulin receptor in the same direction.

  • moderate
    Insulin NPH (Humulin N) + Insulin Lispro (Humalog) Stacked effects

    Insulin Lispro (Humalog) and Insulin NPH (Humulin N) both push the igf1 receptor and insulin receptor in the same direction.

  • moderate
    Insulin Regular (Humulin R) + Insulin Lispro (Humalog) Stacked effects

    Insulin Lispro (Humalog) and Insulin Regular (Humulin R) both push the igf1 receptor and insulin receptor in the same direction.

Serum checks 4 modeled interaction pairings for insulin lispro (humalog) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Reduction of Postprandial Hyperglycemia and Frequency of Hypoglycemia in IDDM Patients on Insulin-Analog Treatment Anderson JH Jr et al. · Diabetes, 1997 DOI

    Pivotal trial establishing that insulin lispro reduced postprandial glucose excursions by 2-3 mmol/L and lowered hypoglycemia rates vs regular human insulin in type 1 diabetes, driving adoption of rapid-acting analogs…

  2. Reduced Frequency of Severe Hypoglycemia and Coma in Well-Controlled IDDM Patients Treated With Insulin Lispro Holleman F et al. · Diabetes Care, 1997 DOI

    Multicenter crossover trial demonstrating insulin lispro reduced severe hypoglycemic events by ~30% and coma episodes significantly compared to regular insulin in intensively treated type 1 diabetes, confirming safety…

  3. Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes (4-T Study) Holman RR et al. · New England Journal of Medicine, 2007 DOI

    Landmark 708-patient trial showing prandial insulin lispro achieved superior HbA1c reduction compared to basal detemir when HbA1c was high, but with more hypoglycemia and weight gain, informing stepwise insulin…

3 published studies referenced in the app, each with a plain-language summary.